Skip to main content

Table 4 MAX41 VOI method relative median differences (%) of MATV, SUV metrics and TLG to corresponding values of EARL1 reconstruction along with 25th and 75th percentiles. Values marked with * indicate that the difference is statistically significant (p < 0.05)

From: Quantitative implications of the updated EARL 2019 PET–CT performance standards

Cancer type

Reconstruction

MATV

SUVmax

SUVpeak

SUVmean

TLG

Tumor SUVmax/liver SUVmax

Tumor SUVmax/liver SUVmean

Lung cancer

EARL_V2

-22* (-31/-15)

30* (22/35)

23* (14/25)

25* (18/36)

-1 (-5/2)

18* (12/22)

29* (23/35)

EARL_V2F6

0 (-6/2)

3* (1/6)

5* (4/7)

3* (2/6)

2 (-1/4)

N/A

N/A

EARL_V2F7

9 (1/14)

-3 (-8/0)

1 (-2/3)

-2 (-7/0)

4 (-2/8)

6* (1/9)

-3 (-8/0)

Lymphoma

EARL_V2

-28* (-36/-19)

35* (22/41)

24* (17/29)

37* (23/42)

-3* (-8/1)

26* (14/30)

35* (22/41)

EARL_V2F6

-7* (-12/-2)

6* (2/13)

6* (3/11)

6* (0/12)

0 (-4/4)

N/A

N/A

EARL_V2F7

0 (-5/7)

0 (-4/4)

2 (-2/4)

0 (-4/4)

0 (-5/5)

6* (1/8)

0 (-4/4)

Both combined

EARL_V2

-27* (-33/-18)

33* (22/40)

23* (16/28)

34* (22/40)

-2* (-7/2)

22* (14/29)

34* (23/39)

EARL_V2F6

-5* (-11/1)

5* (1/11)

5* (3/9)

5* (2/9)

1 (-3/4)

N/A

N/A

EARL_V2F7

2 (-4/11)

-1 (-6/4)

2* (-2/4)

-1 (-5/4)

2 (-4/7)

6* (1/9)

-1 (-6/3)